Atrion (NASDAQ:ATRI) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a research note issued to investors on Tuesday.

Atrion Stock Performance

Atrion stock opened at $462.93 on Tuesday. Atrion has a fifty-two week low of $274.98 and a fifty-two week high of $602.59. The firm’s fifty day moving average price is $428.87 and its 200-day moving average price is $377.16. The stock has a market cap of $814.76 million, a P/E ratio of 43.51 and a beta of 0.62.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter. The firm had revenue of $47.33 million during the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

Atrion Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 14th will be paid a dividend of $2.20 per share. This represents a $8.80 annualized dividend and a dividend yield of 1.90%. The ex-dividend date is Friday, June 14th. Atrion’s dividend payout ratio (DPR) is presently 82.71%.

Institutional Investors Weigh In On Atrion

A number of institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its position in Atrion by 2.0% during the third quarter. Bank of New York Mellon Corp now owns 10,006 shares of the medical instruments supplier’s stock valued at $4,134,000 after buying an additional 194 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Atrion by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock valued at $4,291,000 after acquiring an additional 243 shares during the period. WINTON GROUP Ltd purchased a new stake in Atrion during the 3rd quarter valued at about $208,000. SG Americas Securities LLC bought a new position in Atrion during the 4th quarter worth approximately $108,000. Finally, First Financial Corp IN purchased a new position in Atrion in the 4th quarter worth approximately $136,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.